LYKOS THERAPEUTICS lobbying for LYKOS THERAPEUTICS

Filing 2nd Quarter - Termination

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 21, 2025

Expenses

$90,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Representation ended

Jun 30, 2025

The registrant reported terminating its work for this client.

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 3

HR 3944
Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026
HR 2483
SUPPORT for Patients and Communities Reauthorization Act of 2025
S 2121
SUPPORT for Patients and Communities Reauthorization Act of 2025

Lobbying activity 4

Budget/Appropriations

Issues related to MDMA Assisted Therapy research, education and capacity building to support treating mental health challenges, including PTSD (no bill); issues related to therapeutics and implementation research and development (Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026, H.R. 3944 / no Senate bill number).

Defense

Issues related to MDMA Assisted Therapy research, education and capacity building to support treating mental health challenges, including PTSD (no bill); issues related to therapeutics and implementation research and development (Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026, H.R. 3944 / no Senate bill number).

Health Issues

Issues related to pharmaceutical distribution (SUPPORT for Patients and Communities Reauthorization Act of 2025, H.R. 2483 / S. 2121).

Veterans

Issues related to MDMA Assisted Therapy research, education and capacity building to support treating mental health challenges, including PTSD (no bill); issues related to therapeutics and implementation research and development (Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026, H.R. 3944 / no Senate bill number).